CameronJohnTurtleMD
Hematology • Seattle, WAInstructor, Medicine, University of Washington School of Medicine
Are you Dr. Turtle?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 12 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-228-1025
Summary
- Dr. Cameron Turtle, MD is a hematologist in Seattle, Washington. He is currently licensed to practice medicine in Washington. He is affiliated with Fred Hutch Cancer Center and UW Medicine/University of Washington Medical Center.
Education & Training
University of Sydney Faculty of MedicineClass of 1993
Certifications & Licensure
WA State Medical License 2007 - 2022
Clinical Trials
- JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Start of enrollment: 2016 Nov 15
- huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia Start of enrollment: 2017 Nov 03
Publications & Presentations
PubMed
- Phase I study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult B-ALL patients.Jordan Gauthier, Emily C Liang, Jennifer J Huang, Erik Lesley Kimble, Alexandre V Hirayama
Blood Advances. 2025-01-16 - 2 citationsTargeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapy.Salvatore Fiorenza, Sheryl Y T Lim, George S Laszlo, Erik L Kimble, Tinh-Doan Phi
Molecular Therapy. Oncology. 2024-09-19 - 2 citationsPD-L1macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy effic...Alexandre V Hirayama, Jocelyn H Wright, Kimberly S Smythe, Salvatore Fiorenza, Akira N Shaw
Hemasphere. 2024-08-01
Press Mentions
Patient and Family Experience with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and Polyneuropathy (ATTR-PN) Amyloidosis: Results of Two Focus GroupsFebruary 8th, 2021- Eureka Therapeutics Appoints Nobel Laureate Randy Schekman, Ph.D. To Its Scientific Advisory BoardNovember 9th, 2020
Fred Hutch at ASH: Latest CAR T Data – BCMA, CD19, CD20 – plus New Insights on Transplantation, Gene Therapy – and MoreNovember 21st, 2019- Join now to see all
